Orchid Pharma Limited · NSE:ORCHPHARMA
Orchid Pharma — Shareholder Meeting (July 2021)
12 slides from Orchid Pharma's shareholder meeting presentation, Jul 28, 2021
Slide 1: Disclosure under Regulation 30 of SEBI LODR - Cover Letter
Orch idPharma? | { Formerly known as Orchid Chemicals & Pharmaceuticals Limited } Corp. OFf.: Orchid Pharma Ltd., ‘Orchid Towers’ 313, Valluvarkottam High Road, Nungambakkam, Chennai - 600 034, India. ‘ CIN: £24222TN1992PLC022994 July 28, 2024 National Stock Exchange of India Ltd BSE Limited ° Listi
Slide 2: Proposed Material Related Party Transactions for the Financial Year 2021-2022
ORCHID PHARMA LIMITED PROPOSED MATERIAL RELATED PARTY TRANSACTIONS FOR THE FINANCIAL YEAR 2021-2022
Slide 3: Proposed Material Related Party Transaction with Otsuka Chemicals (India) Private Limited
OrchidPharma? A Dhanuka Group Company Proposed Material Related Party Transaction with M/s. Otsuka Chemicals (India) Private Limited
Slide 4: Transaction between Orchid Pharma and Otsuka Chemicals prior to March 31, 2020
Transaction between Orchid Pharma Limited and Otsuka Chemicals (India) Private Limited prior to March 31,2020 (Prior to the take over by M/s Dhanuka Laboratories Limited ) Otsuka Chemicals Orchid Pharma Limited –Transactions (India) Private (Purchase of goods) with Otsuka Limited Otsuka Chemicals (I
Slide 5: Related party: Otsuka Chemicals (India) Private Limited
Proposed Material Related Party Transaction with M/s. Otsuka Chemicals (India) Private Limited Nature of Proposed value Related party transaction of transaction Mr. Manish Dhanuka, Managing Director of Orchid Pharma Aggregate up to Rs. 75 Crores Limited is also a Director on Recurring & (Rupees Seve
Slide 6: Justification for entering into related party transaction with Otsuka Chemicals
Justification for entering into related party transaction with M/s. Otsuka Chemicals (India) Private Limited Only approved source of the Key Raw Material GCLE for Orchid. Even prior to the takeover by the Dhanuka group, Otsuka was the only approved source for this product Otsuka also buys the end pr
Slide 7: OrBion Pharmaceuticals Private Limited
OrchidPharma? A Dhanuka Group Company Proposed Material Related Party Transaction with M/s.OrBion Pharmaceuticals Private Limited
Slide 8: Rationale for Proposed Material related party transaction with OrBion Pharmaceuticals
Commitment to Bank for hiving off Rationale for Proposed Material IKKT business to return the loan related party transaction with availed by the Company OrBion Pharmaceuticals Private Limited Negative EBIDTA of IKKT business, therefore, transfer of this business will -Transfer of IKKT business impro
Slide 9: Related Party and Nature of transaction: OrBion Pharmaceuticals
Proposed Material Related Party Transaction with M/s. OrBion Pharmaceuticals Private Limited Nature of Related Party transaction Value of transaction - Associate Company Transfer of the Formulations unit of the Orchid Pharma Limited will Orchid Pharma Limited holds Company (IKKT) to M/s. receive con
Slide 10: Justification for entering into Material related party transaction with OrBion
As the IKKT Business is generating negative EBIDTA, hiving off this business will improve the profitability of Orchid. Partnership with Bion Pharma will improve the profitability of IKKT business also, thereby, increasing its future Justification for entering valuation. into Material related party 1
Slide 11: Dhanuka Laboratories Limited
OrchidPharma? A Dhanuka Group Company Proposed Material Related Party Transaction with M/s. Dhanuka Laboratories Limited
Slide 12: Proposed Material Related Party Transaction with Dhanuka Laboratories Limited
Proposed Material Related Party Transaction with M/s. Dhanuka Laboratories Limited Related party M/s. Dhanuka Laboratories Limited by virtue of being holding company & Promoter holding 20% or more of shareholding of the Company Nature and proposed Availment of unsecured loan value of transaction Agg